At the news
? BULLISHIMPACT 7/10 8-K filed Aug 6, 2026 at 07:40 ET
PepGen reported Q2 2026 EPS of -$0.26, beating the -$0.30 consensus by 13.3%, with no revenue. The key catalyst is the DSMB's recommendation to advance PGN-EDODM1 into the highest 12.5 mg/kg dose cohort in the FREEDOM2-DM1 study and to dose-escalate the OLE, confirming a favorable safety profile. The company has $117.2M cash, sufficient into Q4 2027, and expects 10 mg/kg data in November 2026, which is the primary near-term catalyst.
- DSMB recommended advancing FREEDOM2 into the highest 12.5 mg/kg dose cohort with no protocol changes.
- DSMB also approved OLE dose escalation from 5 mg/kg to 10 mg/kg.
- 10 mg/kg FREEDOM2 cohort fully enrolled; 7 of 8 participants completed dosing; data expected November 2026.
- 12.5 mg/kg cohort results expected 1H 2027; EOP2 meeting with regulators planned thereafter.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access